David Tran, MD, PhD

Title(s)Associate Professor of Neurological Surgery and Neurology
SchoolKeck School of Medicine of Usc
Address2250 Alcazar St.
Health Sciences Campus
Los Angeles CA 90033
vCardDownload vCard
    Other Positions
    Title(s)Division Chief, Neuro-Oncology (Neurological Surgery) and Co-Director of the USC Brain Tumor Center (BTC)


    Collapse Overview 
    Collapse Overview
    Dr Tran received his MD and PhD degrees from the Mayo Clinic College of Medicine in 2005 and completed his postgraduate training in Oncology and Neuro-Oncology at Washington University School of Medicine in St Louis in 2011. He is a leader in Precision Medicine with many seminal publications in cancer research and serves as the principal investigator of several national clinical trials in brain cancer. Research in the Tran laboratory focuses on understanding the molecular mechanism of how cancer develops, progresses, and resists treatment through a vertically integrated approach, starting with clinical observations, guided by systems and computational analyses, followed by experimental validation and translation into novel anti-cancer therapeutics.

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. A Spatial Interpolation Approach to Assign Magnetic Resonance Imaging-Derived Material Properties for Finite Element Models of Adeno-Associated Virus Infusion Into a Recurrent Brain Tumor. J Biomech Eng. 2024 10 01; 146(10). Chen R, Rey JA, Tuna IS, Tran DD, Sarntinoranont M. PMID: 38581376; PMCID: PMC11110824.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    2. Machine Learning-Directed Conversion of Glioblastoma Cells to Dendritic Cell-Like Antigen-Presenting Cells as Cancer Immunotherapy. Cancer Immunol Res. 2024 Oct 01; 12(10):1340-1360. Liu T, Jin D, Le SB, Chen D, Sebastian M, Riva A, Liu R, Tran DD. PMID: 39051633; PMCID: PMC11491168.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    3. Patterns and predictors of anxiety and depression symptom trajectories in patients diagnosed with primary brain tumors. J Neurooncol. 2023 Sep; 164(3):701-710. Ernster AE, Body A, Deleyrolle P, St Clair J, Sampson D, Bacharz K, Yan SC, Melnick K, Allen A, Rahman M, Tran DD, Mitchell DA, Pereira DB, Ghiaseddin AP. PMID: 37804375; PMCID: PMC10695656.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    4. Comparison of preoperative versus postoperative treatment dosimetry plans of single-fraction stereotactic radiosurgery for surgically resected brain metastases. Neurosurg Focus. 2023 08; 55(2):E9. Cheok SK, Yu C, Feng JJ, Briggs RG, Chow F, Hwang L, Ye JC, Attenello FJ, Tran D, Chang E, Zada G. PMID: 37527673.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial. JAMA Oncol. 2023 01 01; 9(1):112-121. Liau LM, Ashkan K, Brem S, Campian JL, Trusheim JE, Iwamoto FM, Tran DD, Ansstas G, Cobbs CS, Heth JA, Salacz ME, D'Andre S, Aiken RD, Moshel YA, Nam JY, Pillainayagam CP, Wagner SA, Walter KA, Chaudhary R, Goldlust SA, Lee IY, Bota DA, Elinzano H, Grewal J, Lillehei K, Mikkelsen T, Walbert T, Abram S, Brenner AJ, Ewend MG, Khagi S, Lovick DS, Portnow J, Kim L, Loudon WG, Martinez NL, Thompson RC, Avigan DE, Fink KL, Geoffroy FJ, Giglio P, Gligich O, Krex D, Lindhorst SM, Lutzky J, Meisel HJ, Nadji-Ohl M, Sanchin L, Sloan A, Taylor LP, Wu JK, Dunbar EM, Etame AB, Kesari S, Mathieu D, Piccioni DE, Baskin DS, Lacroix M, May SA, New PZ, Pluard TJ, Toms SA, Tse V, Peak S, Villano JL, Battiste JD, Mulholland PJ, Pearlman ML, Petrecca K, Schulder M, Prins RM, Boynton AL, Bosch ML. PMID: 36394838; PMCID: PMC9673026.
      View in: PubMed   Mentions: 137     Fields:    Translation:HumansCellsPHPublic Health
    6. The trial effect in patients with glioblastoma: effect of clinical trial enrollment on overall survival. J Neurooncol. 2022 Sep; 159(2):479-484. Melnick KF, Miller P, Carmichael E, McGrath K, Ghiaseddin A, Tran DD, Rahman M. PMID: 35840786.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    7. Corrigendum to: A phase II study of laser interstitial thermal therapy combined with doxorubicin in patients with recurrent glioblastoma. Neurooncol Adv. 2022 Jan-Dec; 4(1):vdac042. Butt OH, Zhou AY, Huang J, Leidig WA, Silberstein AE, Chheda MG, Johanns TM, Ansstas G, Liu J, Talcott G, Nakiwala R, Shimony JS, Kim AH, Leuthardt EC, Tran DD, Campian JL. PMID: 35505674; PMCID: PMC9054253.
      View in: PubMed   Mentions: 1  
    8. Tumor Treating Fields dually activate STING and AIM2 inflammasomes to induce adjuvant immunity in glioblastoma. J Clin Invest. 2022 04 15; 132(8). Chen D, Le SB, Hutchinson TE, Calinescu AA, Sebastian M, Jin D, Liu T, Ghiaseddin A, Rahman M, Tran DD. PMID: 35199647; PMCID: PMC9012294.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansAnimalsCells
    9. Tumor Treating Fields: killing two birds with one stone. J Clin Invest. 2022 04 15; 132(8). Lee J, Grabowski MM, Lathia JD. PMID: 35426370; PMCID: PMC9012279.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    10. A phase II study of laser interstitial thermal therapy combined with doxorubicin in patients with recurrent glioblastoma. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab164. Butt OH, Zhou AY, Huang J, Leidig WA, Silberstein AE, Chheda MG, Johanns TM, Ansstas G, Liu J, Talcott G, Nakiwala R, Shimony JS, Kim AH, Leuthardt EC, Tran DD, Campian JL. PMID: 34988450; PMCID: PMC8694207.
      View in: PubMed   Mentions: 18  
    11. Tumor Treating Fields for Glioblastoma Therapy During the COVID-19 Pandemic. Front Oncol. 2021; 11:679702. Gatson NTN, Barnholtz-Sloan J, Drappatz J, Henriksson R, Hottinger AF, Hinoul P, Kruchko C, Puduvalli VK, Tran DD, Wong ET, Glas M. PMID: 34026655; PMCID: PMC8139188.
      View in: PubMed   Mentions: 7  
    12. A Bayesian adaptive randomized phase II multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma. Neuro Oncol. 2020 10 14; 22(10):1505-1515. Puduvalli VK, Wu J, Yuan Y, Armstrong TS, Vera E, Wu J, Xu J, Giglio P, Colman H, Walbert T, Raizer J, Groves MD, Tran D, Iwamoto F, Avgeropoulos N, Paleologos N, Fink K, Peereboom D, Chamberlain M, Merrell R, Penas Prado M, Yung WKA, Gilbert MR. PMID: 32166308; PMCID: PMC7686463.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    13. In situ vaccination with laser interstitial thermal therapy augments immunotherapy in malignant gliomas. J Neurooncol. 2021 Jan; 151(1):85-92. Shin DH, Melnick KF, Tran DD, Ghiaseddin AP. PMID: 32757094.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansPHPublic Health
    14. Tumor Treating Fields in the Management of Patients with Malignant Gliomas. Curr Treat Options Oncol. 2020 07 30; 21(9):76. Ghiaseddin AP, Shin D, Melnick K, Tran DD. PMID: 32734509; PMCID: PMC7391234.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    15. Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial. Clin Cancer Res. 2020 04 01; 26(7):1586-1594. Reardon DA, Desjardins A, Vredenburgh JJ, O'Rourke DM, Tran DD, Fink KL, Nabors LB, Li G, Bota DA, Lukas RV, Ashby LS, Duic JP, Mrugala MM, Cruickshank S, Vitale L, He Y, Green JA, Yellin MJ, Turner CD, Keler T, Davis TA, Sampson JH, ReACT trial investigators. PMID: 32034072.
      View in: PubMed   Mentions: 80     Fields:    Translation:Humans
    16. Combining CDK4/6 inhibitors ribociclib and palbociclib with cytotoxic agents does not enhance cytotoxicity. PLoS One. 2019; 14(10):e0223555. Jin D, Tran N, Thomas N, Tran DD. PMID: 31600301; PMCID: PMC6786609.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    17. Quantitative characterization of 3D bioprinted structural elements under cell generated forces. Nat Commun. 2019 07 10; 10(1):3029. Morley CD, Ellison ST, Bhattacharjee T, O'Bryan CS, Zhang Y, Smith KF, Kabb CP, Sebastian M, Moore GL, Schulze KD, Niemi S, Sawyer WG, Tran DD, Mitchell DA, Sumerlin BS, Flores CT, Angelini TE. PMID: 31292444; PMCID: PMC6620298.
      View in: PubMed   Mentions: 27     Fields:    Translation:AnimalsCells
    18. A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872. Cancer. 2019 11 01; 125(21):3790-3800. Galanis E, Anderson SK, Twohy EL, Carrero XW, Dixon JG, Tran DD, Jeyapalan SA, Anderson DM, Kaufmann TJ, Feathers RW, Giannini C, Buckner JC, Anastasiadis PZ, Schiff D. PMID: 31290996; PMCID: PMC6788934.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCTClinical Trials
    19. Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med. 2018 06 29; 16(1):179. Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, Iwamoto FM, Dropcho EJ, Moshel YA, Walter KA, Pillainayagam CP, Aiken R, Chaudhary R, Goldlust SA, Bota DA, Duic P, Grewal J, Elinzano H, Toms SA, Lillehei KO, Mikkelsen T, Walbert T, Abram SR, Brenner AJ, Brem S, Ewend MG, Khagi S, Portnow J, Kim LJ, Loudon WG, Thompson RC, Avigan DE, Fink KL, Geoffroy FJ, Lindhorst S, Lutzky J, Sloan AE, Schackert G, Krex D, Meisel HJ, Wu J, Davis RP, Duma C, Etame AB, Mathieu D, Kesari S, Piccioni D, Westphal M, Baskin DS, New PZ, Lacroix M, May SA, Pluard TJ, Tse V, Green RM, Villano JL, Pearlman M, Petrecca K, Schulder M, Taylor LP, Maida AE, Prins RM, Cloughesy TF, Mulholland P, Bosch ML. PMID: 29958537; PMCID: PMC6026340.
      View in: PubMed   Mentions: 10     Fields:    
    20. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med. 2018 05 29; 16(1):142. Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, Iwamoto FM, Dropcho EJ, Moshel YA, Walter KA, Pillainayagam CP, Aiken R, Chaudhary R, Goldlust SA, Bota DA, Duic P, Grewal J, Elinzano H, Toms SA, Lillehei KO, Mikkelsen T, Walbert T, Abram SR, Brenner AJ, Brem S, Ewend MG, Khagi S, Portnow J, Kim LJ, Loudon WG, Thompson RC, Avigan DE, Fink KL, Geoffroy FJ, Lindhorst S, Lutzky J, Sloan AE, Schackert G, Krex D, Meisel HJ, Wu J, Davis RP, Duma C, Etame AB, Mathieu D, Kesari S, Piccioni D, Westphal M, Baskin DS, New PZ, Lacroix M, May SA, Pluard TJ, Tse V, Green RM, Villano JL, Pearlman M, Petrecca K, Schulder M, Taylor LP, Maida AE, Prins RM, Cloughesy TF, Mulholland P, Bosch ML. PMID: 29843811; PMCID: PMC5975654.
      View in: PubMed   Mentions: 278     Fields:    Translation:HumansCellsCTClinical Trials
    21. Biological and therapeutic implications of multisector sequencing in newly diagnosed glioblastoma. Neuro Oncol. 2018 03 27; 20(4):472-483. Mahlokozera T, Vellimana AK, Li T, Mao DD, Zohny ZS, Kim DH, Tran DD, Marcus DS, Fouke SJ, Campian JL, Dunn GP, Miller CA, Kim AH. PMID: 29244145; PMCID: PMC5909635.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    22. Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma. J Neurooncol. 2018 May; 138(1):105-111. Huang J, Campian JL, Gujar AD, Tsien C, Ansstas G, Tran DD, DeWees TA, Lockhart AC, Kim AH. PMID: 29374809.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    23. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA. 2017 12 19; 318(23):2306-2316. Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran D, Brem S, Hottinger A, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Bruna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z. PMID: 29260225; PMCID: PMC5820703.
      View in: PubMed   Mentions: 1125     Fields:    Translation:HumansCTClinical Trials
    24. Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - Authors' reply. Lancet Oncol. 2017 12; 18(12):e709-e710. Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, Drappatz J, O'Rourke DM, Wong M, Hamilton MG, Finocchiaro G, Perry J, Wick W, Green J, He Y, Turner CD, Yellin MJ, Keler T, Davis TA, Stupp R, Sampson JH. PMID: 29208433.
      View in: PubMed   Mentions: 2     Fields:    
    25. Eleven Month Progression-Free Survival on Vemurafenib Monotherapy in a Patient With Recurrent and Metastatic BRAF V600E-Mutated Glioblastoma WHO Grade 4. JCO Precis Oncol. 2017 Nov; 1:1-5. Beba Abadal K, Walsh MA, Yachnis AT, Tran DD, Ghiaseddin AP. PMID: 35172504.
      View in: PubMed   Mentions: 9     Fields:    
    26. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol. 2017 10; 18(10):1373-1385. Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, Drappatz J, O'Rourke DM, Wong M, Hamilton MG, Finocchiaro G, Perry J, Wick W, Green J, He Y, Turner CD, Yellin MJ, Keler T, Davis TA, Stupp R, Sampson JH, ACT IV trial investigators. PMID: 28844499.
      View in: PubMed   Mentions: 555     Fields:    Translation:HumansCTClinical Trials
    27. An NAD+-dependent transcriptional program governs self-renewal and radiation resistance in glioblastoma. Proc Natl Acad Sci U S A. 2016 12 20; 113(51):E8247-E8256. Gujar AD, Le S, Mao DD, Dadey DY, Turski A, Sasaki Y, Aum D, Luo J, Dahiya S, Yuan L, Rich KM, Milbrandt J, Hallahan DE, Yano H, Tran DD, Kim AH. PMID: 27930300; PMCID: PMC5187672.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansAnimalsCells
    28. Molecular and histologic characteristics of pseudoprogression in diffuse gliomas. J Neurooncol. 2016 12; 130(3):529-533. Lin AL, White M, Miller-Thomas MM, Fulton RS, Tsien CI, Rich KM, Schmidt RE, Tran DD, Dahiya S. PMID: 27704386; PMCID: PMC5518746.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    29. A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy. J Neurooncol. 2016 06; 128(2):259-66. Huang J, Campian JL, Gujar AD, Tran DD, Lockhart AC, DeWees TA, Tsien CI, Kim AH. PMID: 26966095.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCTClinical Trials
    30. Hyperthermic Laser Ablation of Recurrent Glioblastoma Leads to Temporary Disruption of the Peritumoral Blood Brain Barrier. PLoS One. 2016; 11(2):e0148613. Leuthardt EC, Duan C, Kim MJ, Campian JL, Kim AH, Miller-Thomas MM, Shimony JS, Tran DD. PMID: 26910903; PMCID: PMC4766093.
      View in: PubMed   Mentions: 82     Fields:    Translation:Humans
    31. Treatment with Tumor-Treating Fields Therapy and Pulse Dose Bevacizumab in Patients with Bevacizumab-Refractory Recurrent Glioblastoma: A Case Series. Case Rep Neurol. 2016 Jan-Apr; 8(1):1-9. Ansstas G, Tran DD. PMID: 26889149; PMCID: PMC4748800.
      View in: PubMed   Mentions: 10  
    32. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA. 2015 Dec 15; 314(23):2535-43. Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink KL, Barnett GH, Zhu JJ, Henson JW, Engelhard HH, Chen TC, Tran DD, Sroubek J, Tran ND, Hottinger AF, Landolfi J, Desai R, Caroli M, Kew Y, Honnorat J, Idbaih A, Kirson ED, Weinberg U, Palti Y, Hegi ME, Ram Z. PMID: 26670971.
      View in: PubMed   Mentions: 573     Fields:    Translation:HumansCTClinical Trials
    33. Central Nervous System Cancers, Version 1.2015. J Natl Compr Canc Netw. 2015 Oct; 13(10):1191-202. Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Brown P, Butowski N, Chamberlain MC, Fenstermaker RA, Friedman A, Gilbert MR, Hattangadi-Gluth J, Holdhoff M, Junck L, Kaley T, Lawson R, Loeffler JS, Lovely MP, Moots PL, Mrugala MM, Newton HB, Parney I, Raizer JJ, Recht L, Shonka N, Shrieve DC, Sills AK, Swinnen LJ, Tran D, Tran N, Vrionis FD, Weiss S, Wen PY, McMillian N, Engh AM. PMID: 26483059.
      View in: PubMed   Mentions: 59     Fields:    Translation:Humans
    34. Aerobic Glycolysis as a Marker of Tumor Aggressiveness: Preliminary Data in High Grade Human Brain Tumors. Dis Markers. 2015; 2015:874904. Vlassenko AG, McConathy J, Couture LE, Su Y, Massoumzadeh P, Leeds HS, Chicoine MR, Tran DD, Huang J, Dahiya S, Marcus DS, Fouke SJ, Rich KM, Raichle ME, Benzinger TL. PMID: 26424903; PMCID: PMC4573613.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    35. A CDC20-APC/SOX2 Signaling Axis Regulates Human Glioblastoma Stem-like Cells. Cell Rep. 2015 Jun 23; 11(11):1809-21. Mao DD, Gujar AD, Mahlokozera T, Chen I, Pan Y, Luo J, Brost T, Thompson EA, Turski A, Leuthardt EC, Dunn GP, Chicoine MR, Rich KM, Dowling JL, Zipfel GJ, Dacey RG, Achilefu S, Tran DD, Yano H, Kim AH. PMID: 26074073; PMCID: PMC4481182.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansAnimalsCells
    36. Clinical and Dosimetric Predictors of Acute Severe Lymphopenia During Radiation Therapy and Concurrent Temozolomide for High-Grade Glioma. Int J Radiat Oncol Biol Phys. 2015 Aug 01; 92(5):1000-1007. Huang J, DeWees TA, Badiyan SN, Speirs CK, Mullen DF, Fergus S, Tran DD, Linette G, Campian JL, Chicoine MR, Kim AH, Dunn G, Simpson JR, Robinson CG. PMID: 26025775.
      View in: PubMed   Mentions: 54     Fields:    Translation:Humans
    37. Impact of 1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide. Int J Radiat Oncol Biol Phys. 2015 Feb 01; 91(2):268-76. Speirs CK, Simpson JR, Robinson CG, DeWees TA, Tran DD, Linette G, Chicoine MR, Dacey RG, Rich KM, Dowling JL, Leuthardt EC, Zipfel GJ, Kim AH, Huang J. PMID: 25636755.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    38. Stereotactic laser ablation of high-grade gliomas. Neurosurg Focus. 2014 Dec; 37(6):E1. Hawasli AH, Kim AH, Dunn GP, Tran DD, Leuthardt EC. PMID: 25434378.
      View in: PubMed   Mentions: 49     Fields:    Translation:Humans
    39. Central nervous system cancers, version 2.2014. Featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2014 Nov; 12(11):1517-23. Nabors LB, Portnow J, Ammirati M, Brem H, Brown P, Butowski N, Chamberlain MC, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hattangadi-Gluth J, Hesser D, Holdhoff M, Junck L, Lawson R, Loeffler JS, Moots PL, Mrugala MM, Newton HB, Raizer JJ, Recht L, Shonka N, Shrieve DC, Sills AK, Swinnen LJ, Tran D, Tran N, Vrionis FD, Wen PY, McMillian NR, Ho M. PMID: 25361798; PMCID: PMC4337873.
      View in: PubMed   Mentions: 42     Fields:    Translation:Humans
    40. Radiation therapy dose escalation for glioblastoma multiforme in the era of temozolomide. Int J Radiat Oncol Biol Phys. 2014 Nov 15; 90(4):877-85. Badiyan SN, Markovina S, Simpson JR, Robinson CG, DeWees T, Tran DD, Linette G, Jalalizadeh R, Dacey R, Rich KM, Chicoine MR, Dowling JL, Leuthardt EC, Zipfel GJ, Kim AH, Huang J. PMID: 25257812.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    41. Clinical practice experience with NovoTTF-100A™ system for glioblastoma: The Patient Registry Dataset (PRiDe). Semin Oncol. 2014 Oct; 41 Suppl 6:S4-S13. Mrugala MM, Engelhard HH, Dinh Tran D, Kew Y, Cavaliere R, Villano JL, Annenelie Bota D, Rudnick J, Love Sumrall A, Zhu JJ, Butowski N. PMID: 25213869.
      View in: PubMed   Mentions: 79     Fields:    Translation:Humans
    42. Transient SNAIL1 expression is necessary for metastatic competence in breast cancer. Cancer Res. 2014 Nov 01; 74(21):6330-40. Tran HD, Luitel K, Kim M, Zhang K, Longmore GD, Tran DD. PMID: 25164016; PMCID: PMC4925010.
      View in: PubMed   Mentions: 126     Fields:    Translation:HumansCells
    43. Characterization and management of dermatologic adverse events with the NovoTTF-100A System, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma. Semin Oncol. 2014 Jun; 41 Suppl 4:S1-14. Lacouture ME, Davis ME, Elzinga G, Butowski N, Tran D, Villano JL, DiMeglio L, Davies AM, Wong ET. PMID: 24794308.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    44. Codeletions at 1p and 19q predict a lower risk of pseudoprogression in oligodendrogliomas and mixed oligoastrocytomas. Neuro Oncol. 2014 Jan; 16(1):123-30. Lin AL, Liu J, Evans J, Leuthardt EC, Rich KM, Dacey RG, Dowling JL, Kim AH, Zipfel GJ, Grubb RL, Huang J, Robinson CG, Simpson JR, Linette GP, Chicoine MR, Tran DD. PMID: 24285548; PMCID: PMC3870829.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    45. Central nervous system cancers. J Natl Compr Canc Netw. 2013 Sep 01; 11(9):1114-51. Nabors LB, Ammirati M, Bierman PJ, Brem H, Butowski N, Chamberlain MC, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hesser D, Holdhoff M, Junck L, Lawson R, Loeffler JS, Maor MH, Moots PL, Morrison T, Mrugala MM, Newton HB, Portnow J, Raizer JJ, Recht L, Shrieve DC, Sills AK, Tran D, Tran N, Vrionis FD, Wen PY, McMillian N, Ho M, National Comprehensive Cancer Network. PMID: 24029126; PMCID: PMC4124889.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    46. Antiangiogenic agents for nonmalignant brain tumors. J Neurol Surg B Skull Base. 2013 Jun; 74(3):136-41. Hawasli AH, Rubin JB, Tran DD, Adkins DR, Waheed S, Hullar TE, Gutmann DH, Evans J, Leonard JR, Zipfel GJ, Chicoine MR. PMID: 24436903; PMCID: PMC3709924.
      View in: PubMed   Mentions: 18  
    47. Temporal and spatial cooperation of Snail1 and Twist1 during epithelial-mesenchymal transition predicts for human breast cancer recurrence. Mol Cancer Res. 2011 Dec; 9(12):1644-57. Tran DD, Corsa CA, Biswas H, Aft RL, Longmore GD. PMID: 22006115; PMCID: PMC4922748.
      View in: PubMed   Mentions: 99     Fields:    Translation:HumansCells
    48. CAML loss causes anaphase failure and chromosome missegregation. Cell Cycle. 2009 Mar 15; 8(6):940-9. Liu Y, Malureanu L, Jeganathan KB, Tran DD, Lindquist LD, van Deursen JM, Bram RJ. PMID: 19229138; PMCID: PMC2967022.
      View in: PubMed   Mentions: 13     Fields:    Translation:AnimalsCells
    49. Calcium-modulating cyclophilin ligand regulates membrane trafficking of postsynaptic GABA(A) receptors. Mol Cell Neurosci. 2008 Jun; 38(2):277-89. Yuan X, Yao J, Norris D, Tran DD, Bram RJ, Chen G, Luscher B. PMID: 18424167; PMCID: PMC2350232.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansAnimalsCells
    50. CAML is a p56Lck-interacting protein that is required for thymocyte development. Immunity. 2005 Aug; 23(2):139-52. Tran DD, Edgar CE, Heckman KL, Sutor SL, Huntoon CJ, van Deursen J, McKean DL, Bram RJ. PMID: 16111633.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimalsCells
    51. Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol Cell Biol. 2004 Sep; 24(18):8195-209. Trushina E, Dyer RB, Badger JD, Ure D, Eide L, Tran DD, Vrieze BT, Legendre-Guillemin V, McPherson PS, Mandavilli BS, Van Houten B, Zeitlin S, McNiven M, Aebersold R, Hayden M, Parisi JE, Seeberg E, Dragatsis I, Doyle K, Bender A, Chacko C, McMurray CT. PMID: 15340079; PMCID: PMC515048.
      View in: PubMed   Mentions: 228     Fields:    Translation:HumansAnimalsCells
    52. CAML is required for efficient EGF receptor recycling. Dev Cell. 2003 Aug; 5(2):245-56. Tran DD, Russell HR, Sutor SL, van Deursen J, Bram RJ. PMID: 12919676.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansAnimalsCells
    53. Cyclin G2 is up-regulated during growth inhibition and B cell antigen receptor-mediated cell cycle arrest. J Biol Chem. 1997 May 09; 272(19):12650-61. Horne MC, Donaldson KL, Goolsby GL, Tran D, Mulheisen M, Hell JW, Wahl AF. PMID: 9139721.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansAnimalsCells
    54. Cyclin G1 and cyclin G2 comprise a new family of cyclins with contrasting tissue-specific and cell cycle-regulated expression. J Biol Chem. 1996 Mar 15; 271(11):6050-61. Horne MC, Goolsby GL, Donaldson KL, Tran D, Neubauer M, Wahl AF. PMID: 8626390.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansAnimalsCells
    David's Networks
    Concepts (284)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (16)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    NIH Funding Acknowledgment: Important - All publications resulting from the utilization of SC CTSI resources are required to credit the SC CTSI grant by including the NIH funding acknowledgment and must comply with the NIH Public Access Policy.

    This site is running Profiles RNS version UCSF-v3.1.0-6-g69de2244 on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.